10-Year Follow-Up: Pembrolizumab Outshines Ipilimumab in Advanced Melanoma
Long-term study shows pembrolizumab's superior efficacy over ipilimumab for advanced melanoma patients.
Subcutaneous Nivolumab: A Game-Changer for Advanced Kidney Cancer Treatment
Subcutaneous nivolumab proves noninferior to IV administration in advanced kidney cancer patients.
New Hope in Lung Cancer: Dostarlimab Rivals Pembrolizumab in First-Line Treatment
Phase II trial shows dostarlimab plus chemo matches pembrolizumab efficacy for metastatic NSCLC patients.
New Hope for Acute Myeloid Leukemia: Cusatuzumab Shows Promise in Clinical Trial
Cusatuzumab plus azacitidine shows efficacy in treating newly diagnosed acute myeloid leukemia
Latest
10-Year Follow-Up: Pembrolizumab Outshines Ipilimumab in Advanced Melanoma
Long-term study shows pembrolizumab's superior efficacy over ipilimumab for advanced melanoma patients.
Durvalumab vs Cetuximab: No Advantage in Head and Neck Cancer Trial
Study finds durvalumab with radiotherapy no better than cetuximab for cisplatin-ineligible head and neck cancer
Timing is Everything: Early Chemotherapy Boosts Colorectal Cancer Survival
Study finds starting chemotherapy within 6 weeks after colorectal cancer surgery improves survival rates.
Extended Imatinib Therapy Slashes Recurrence Risk in High-Risk GIST Patients
Study shows 6 years of adjuvant imatinib significantly reduces relapse risk in high-risk GIST patients.
EMERALD-1 Trial: Immunotherapy Combo Boosts Survival in Liver Cancer
Adding durvalumab and bevacizumab to TACE improves progression-free survival in hepatocellular carcinoma.
High-Fiber Diet Trial Aims to Boost Immunotherapy Success in Melanoma Patients
New study explores how high-fiber diet affects gut microbiome and immune response in melanoma patients
Promising Results for Neoadjuvant Immunotherapy in Advanced Melanoma
Phase 1/2 trial shows high response rates for pembrolizumab-based neoadjuvant regimens in stage IIIB-D melanoma
DESTINY-Breast06 Trial: Trastuzumab Deruxtecan Shows Promise in HER2-Low Breast Cancer
Trastuzumab deruxtecan outperforms chemotherapy in HER2-low metastatic breast cancer clinical trial.